2015
DOI: 10.1016/j.schres.2014.11.031
|View full text |Cite
|
Sign up to set email alerts
|

Effects of minocycline add-on treatment on brain morphometry and cerebral perfusion in recent-onset schizophrenia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
28
0
2

Year Published

2015
2015
2022
2022

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 36 publications
(32 citation statements)
references
References 46 publications
2
28
0
2
Order By: Relevance
“…In a recent meta-analysis, it was concluded that minocycline is superior to placebo for decreasing PANSS (positive and negative syndrome scale) total scores, PANSS negative subscale scores, and PANSS general subscale scores (Oya et al, 2014). In addition, two more recent randomized controlled trials produced results supporting the effectiveness of minocycline as an adjuvant treatment with antipsychotic drugs for treating negative symptoms of patients with schizophrenia (Chaves et al, 2015;Ghanizadeh et al, 2014). Regarding NSAIDs, a recent meta-analysis concluded that celecoxib augmentation could be a potentially useful strategy to reduce symptom severity in schizophrenia (Sommer et al, 2012), although further studies are needed before a definite conclusion can be accepted.…”
Section: Discussionmentioning
confidence: 99%
“…In a recent meta-analysis, it was concluded that minocycline is superior to placebo for decreasing PANSS (positive and negative syndrome scale) total scores, PANSS negative subscale scores, and PANSS general subscale scores (Oya et al, 2014). In addition, two more recent randomized controlled trials produced results supporting the effectiveness of minocycline as an adjuvant treatment with antipsychotic drugs for treating negative symptoms of patients with schizophrenia (Chaves et al, 2015;Ghanizadeh et al, 2014). Regarding NSAIDs, a recent meta-analysis concluded that celecoxib augmentation could be a potentially useful strategy to reduce symptom severity in schizophrenia (Sommer et al, 2012), although further studies are needed before a definite conclusion can be accepted.…”
Section: Discussionmentioning
confidence: 99%
“…In cuprizone-fed C57BL/6 mice, minocycline reduced microglial activation and demyelination in the brain and prevented disturbances in motor coordination (Pasquini et al, 2007;Skripuletz et al, 2010;Tanaka et al, 2013). Furthermore, minocycline in combination with an antipsychotic such as risperidone, olanzapine, quetiapine, or clozapine significantly improved positive, negative, and cognitive symptoms in recent-onset or chronic schizophrenia patients (Levkovitz et al, 2010;Ghanizadeh et al, 2014;Chaves et al, 2015;Kelly et al, 2015). From these results, it is likely that application of minocycline can dampen M1 signaling, subsequently resulting in skewing of M2a microglia that reduce proinflammatory signaling and increase production of anti-inflammatory cytokines.…”
Section: Pharmacological Approach To Neuroinflammation In Asd and Schmentioning
confidence: 99%
“…Furthermore, a later meta-analysis including two of RCTs 149,150 published after the first meta-analysis, concluded that minocycline was superior to placebo for decreasing PANSS total scores, PANSS negative subscale scores and PANSS general subscale scores 151 . In line with the above conclusion, two more recent RCTs produced results supporting the effectiveness of minocycline, as an adjuvant treatment with antipsychotic drugs for treating negative symptoms of patients with schizophrenia 152,153 . In addition to significantly reducing positive and negative symptoms, when compared with placebo, add-on of minocycline ameliorated the gray matter volume decrease in the mid-posterior cingulate cortex and in the precentral gyrus shown in the patients in the placebo group, suggesting that minocycline may protect against gray matter loss and modulate fronto-temporal areas involved in the pathophysiology of schizophrenia 153 .…”
Section: Minocyclinementioning
confidence: 64%